The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of biomarker-driven early discontinuation of anti–PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192.
 
Geoffrey Thomas Gibney
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Exicure; Genentech; Merck; Novartis; Regeneron; Sapience Therapeutics
Research Funding - Exelixis (Inst); Lucerno Dynamics (Inst)
Other Relationship - Genentech
 
Sandra J. Lee
Employment - ImmunityBio (I)
Stock and Other Ownership Interests - ImmunityBio (I)
Consulting or Advisory Role - Roche/Genentech
 
Michael B. Atkins
Stock and Other Ownership Interests - Pyxis; Werewolf Pharma
Consulting or Advisory Role - Adagene; Agenus; Asher Biotherapeutics; AstraZeneca; Aveo; Bristol-Myers Squibb; Calithera Biosciences; Cota Healthcare; Eisai; Ellipses Pharma; Exelixis; Fathom Biotechnology; Genentech; GlaxoSmithKline; Idera; Iovance Biotherapeutics; Leads Biolabs; Merck; Novartis; Oncorena; PACT Pharma; Pfizer; Pneuma Respiratory; Pyxis; Sanofi; Scholar Rock; Seagen; Simcha Therapeutics; Surface Oncology; Takeda; Werewolf Pharma
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
 
Terence Z. Wong
Consulting or Advisory Role - GE Healthcare
Research Funding - Blue Earth Diagnostics (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - GE Healthcare
 
Jennifer Guerriero
Consulting or Advisory Role - Array BioPharma; Codagenix; Duke Street Bio; GlaxoSmithKline; Immunitas; Kowa Pharmaceutical; Pfizer; Verseau Therapeutics
Research Funding - Array BioPharma/Pfizer; GlaxoSmithKline; Lilly
 
Thomas Urban Marron
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celldex; DBV Technologies; Glenmark; NGM Biopharmaceuticals; Regeneron; Surface Oncology
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - Patent on the combined use of IL4 blockade and PD-1 blockade. (Inst); Patient on the neoadjuvant use of cemiplimab for the treatment of HCC
 
Gary Irvin Cohen
Stock and Other Ownership Interests - Abbvie; Nymox
Speakers' Bureau - Potomac Center for Medical Education
 
Thach-Giao Truong
No Relationships to Disclose
 
Richard D. Carvajal
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Aura Biosciences; Bristol-Myers Squibb/Medarex (Inst); Castle Biosciences; Chimeron Bio; Corvus Pharmaceuticals (Inst); Genzyme; Genzyme; IDEAYA Biosciences (Inst); Immunocore; InxMed; Iovance Biotherapeutics; Merck; Mirati Therapeutics (Inst); Novartis (Inst); Oncosec; Pfizer (Inst); Pierre Fabre; Plexxikon (Inst); PureTech; Regeneron; Regeneron; Rgenix; Roche/Genentech (Inst); Roche/Genentech (Inst); Sorrento Therapeutics; TriSalus Life Sciences
Speakers' Bureau - Bristol-Myers Squibb/Medarex
Research Funding - Amgen (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
 
Bradley Snyder
No Relationships to Disclose
 
Michael Farwell
Consulting or Advisory Role - ImaginAb
Research Funding - Carisma Therapeutics; Celgene/Bristol-Myers Squibb; ImaginAb; Merck
 
John M. Kirkwood
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Amgen; Ankyra Therapeutics; AXIO Research; Becker Pharmaceutical Consulting; Checkmate Pharmaceuticals; DermTech; Fenix Group International; Harbour BioMed; Immunocore; Intellisphere, LLC; Iovance Biotherapeutics; IQVIA; Istari Oncology; Merck; Natera; Novartis; Oncocyte; OncoSec; Pfizer; Replimune; Scopus BioPharma; SR One Capital Management; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Checkmate Pharmaceuticals (Inst); Harbour BioMed (Inst); Immunocore (Inst); Immvira (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Novartis (Inst); Schering-Plough (Inst); Takeda (Inst); Verastem (Inst)
 
Jedd D. Wolchok
Stock and Other Ownership Interests - Apricity Therapeutics; Arsenal IO; Ascentage Pharma; Beigene; Georgiamune; Imvaq Therapeutics; Linnaeus Therapeutics; Maverick Therapeutics; Tizona Therapeutics, Inc.; Trieza Therapeutics
Consulting or Advisory Role - Amgen; Apricity Therapeutics; Ascentage Pharma; AstraZeneca; Bicara Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; CellCarta; Daiichi Sankyo,Inc; Dragonfly Therapeutics; Georgiamune; Idera; Imvaq Therapeutics; Larkspur; Maverick Therapeutics; PsiOxus Therapeutics; Recepta Biopharma; Sellas Life Sciences; Surface Oncology; Tizona Therapeutics, Inc.; Trishula Therapeutics; Truvax; Werewolf Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Sephora
Patents, Royalties, Other Intellectual Property - ALPHAVIRUS REPLICON PARTICLES EXPRESSING TRP2 (Inst); Anti-GITR antibodies and methods of use thereof (Inst); Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof (Inst); Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof CTLA 4 (Inst); CD40 BINDING MOLECULES AND USES THEREOF (Inst); CD40 binding Molecules and uses thereof (Inst); Engineered Vaccinia Viruses for Cancer Immunotherapy (Inst); I am a co-inventor and receive royalties for a blood test for monitoring myeloid derived suppressor cells. (Inst); I am a co-inventor on a patent for Anti-CD40 agonist mAb fused to Monophosphoryl Lipid A (MPL) for cancer therapy (Inst); I am a co-inventor on a patent for CAR+ T cells targeting differentiation antigens as means to treat cancer (Inst); I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus. (Inst); I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals. (Inst); I am co-inventor and receive royalties for a patent for immune modulating antibodies. (Inst); Immunosuppressive follicular helper-like T cells modulated by immune checkpoint blockade (Inst); Peripheral Blood Phenotype Linked to Outcomes After Immunotherapy Treatment (Inst); Phosphatidylserine Targeting Agents and uses thereof for adoptive T-cell therapies (Inst); RECOMBINANT POXVIRUSES FOR CANCER IMMUNOTHERAPY (Inst); WITH IMMUNOMODULATORY THERAPEUTICS AND METHOD OF MONITORING ABSCOPAL EFFECTS DURING SUCH TREATMENT (Inst)